Table 7. **Associations of PTEN, ATAD1, and Stathmin mRNA Levels in Independent Datasets**

Dataset	Carcinoma Type	Number of Samples in Dataset	PTEN levels by signature classification	PTEN levels to signature score, Pearson r, P-value	ATAD1 levels by signature classification	ATAD1 levels to signature score	Stathmin levels by signature classification	Stathmin levels to signature score
van de Vijver	Breast	295	P=0.0004 (N=295)	r=-0.289, P<0.0001 (N=295)	NS (N=292)	NS (N=292)	P<0.0001 (N=295)	r=0.690, P<0.0001
Sotiriou	Breast	99	NS (N=96)	NS (N=96)	P=0.0336 (N=99)	r=-0.183, P=0.0696 (N=99)	NP	NP
Beer	Lung	86	NS (N=86)	NS (N=86)	NP	NP	NP	NP
Blaveri	Bladder	80	NS (N=71)	NS (N=71)	NS (N=65)	NS (N=65)	NP	NP
Glinsky	Prostate	79	NS (N=79)	r=-0.194, P=0.0869 (N=79)	NP	NP	P=0.0511 (N=79)	r=0.273, P=0.0151 (N=79)

Note: The gene expression levels of each gene were tested whether they were significantly lower (PTEN and ATAD1) or higher (Stathmin) in the classified Signature Present group compared to the Signature Absent group using the Mann-Whitney test. The association of the gene expression levels to the PTEN signature score was ascertained using Pearson's correlation coefficient. The number of datapoints available for each test is given within parentheses. Tests with P-values above 0.10 are reported as not significant (NS). When a given gene was not present in the dataset, it is designated NP.